Engineered immune cells take on Hard-to-Treat ovarian cancer
NCT ID NCT03017131
First seen Apr 11, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This early-stage trial tests a new treatment for ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard therapy. Patients receive their own immune cells (T cells) that have been genetically modified to recognize and attack cancer cells, along with a drug called decitabine that may make the cancer cells easier to target. The main goal is to check the safety of this combination in a small group of 9 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.